Campbell & CO Investment Adviser LLC Makes New $561,000 Investment in Tandem Diabetes Care, Inc. $TNDM

Campbell & CO Investment Adviser LLC purchased a new stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 30,108 shares of the medical device company’s stock, valued at approximately $561,000.

A number of other institutional investors also recently modified their holdings of TNDM. Cerity Partners LLC raised its holdings in Tandem Diabetes Care by 32.2% in the 1st quarter. Cerity Partners LLC now owns 76,005 shares of the medical device company’s stock worth $1,456,000 after acquiring an additional 18,529 shares during the period. Envestnet Asset Management Inc. grew its position in shares of Tandem Diabetes Care by 25.4% in the first quarter. Envestnet Asset Management Inc. now owns 318,530 shares of the medical device company’s stock valued at $6,103,000 after purchasing an additional 64,467 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at about $4,457,000. HighTower Advisors LLC increased its stake in shares of Tandem Diabetes Care by 604.6% in the first quarter. HighTower Advisors LLC now owns 67,168 shares of the medical device company’s stock worth $1,287,000 after purchasing an additional 57,635 shares during the period. Finally, Allianz Asset Management GmbH acquired a new position in shares of Tandem Diabetes Care during the 1st quarter worth about $205,000.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ TNDM opened at $18.61 on Friday. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of -6.10 and a beta of 1.51. Tandem Diabetes Care, Inc. has a one year low of $9.98 and a one year high of $38.28. The business has a fifty day simple moving average of $14.19 and a 200 day simple moving average of $16.21. The company has a current ratio of 2.44, a quick ratio of 1.90 and a debt-to-equity ratio of 2.33.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Thursday, November 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). Tandem Diabetes Care had a negative net margin of 20.19% and a negative return on equity of 73.97%. The firm had revenue of $249.25 million for the quarter, compared to analyst estimates of $235.80 million. During the same quarter in the previous year, the firm posted ($0.35) EPS. The business’s revenue for the quarter was up 2.2% on a year-over-year basis. Tandem Diabetes Care has set its FY 2025 guidance at EPS. Sell-side analysts expect that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on TNDM. Wall Street Zen raised Tandem Diabetes Care from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Morgan Stanley increased their price objective on Tandem Diabetes Care from $13.00 to $17.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Oppenheimer began coverage on shares of Tandem Diabetes Care in a research report on Monday, September 8th. They set an “outperform” rating and a $22.00 target price on the stock. Barclays increased their price target on shares of Tandem Diabetes Care from $51.00 to $55.00 and gave the company an “overweight” rating in a report on Monday, November 10th. Finally, UBS Group decreased their price target on shares of Tandem Diabetes Care from $20.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, August 7th. Four research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $21.25.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.